Page 1

innate pharma Innate Pharma First Quarter 2021 Report May 11 , 2021 Marseille , France , May 11 , 2021 ( GLOBE NEWSWIRE ) -- • Lacutamab TELLOMAK trial progresses as KIR3DL2 - expressing mycosis fungoides cohort advances to Stage 2 after positive early signal • Company's first NK cell engager selected by Sanofi as drug candidate for development • Cash position of € 181.7 million¹ as of March 31 , 2021 Innate Pharma SA ( Euronext Paris : IPH - ISIN : FR0010331421 ; Nasdaq : IPHA ) ( " Innate " or the " Company " ) today reported its revenue and cash position for the three - month period ending March 31 , 2021 . " This quarter , we have continued to execute against our strategy , successfully progressing the lacutamab TELLOMAK trial in the mycosis fungoides cohort while also advancing our first NK cell engager with our partner , Sanofi , " said Mondher Mahjoubi , Chief Executive Officer of Innate Pharma . " As we continue to advance our business , we look forward to delivering additional data read - outs from these programs this year , as well as leveraging our strong R & D competencies to lead the next wave of scientific innovation at Innate . " Webcast and conference call will be held today at 3:00 pm CEST ( 9:00 am ET ) Access to live webcast : https://edge.media-server.com/mmc/p/o65bcx4w Participants may also join via telephone by registering in advance of the event at http://emea.directeventreg.com/registration/1570429 . Upon registration , participants will be provided with dial - in numbers , a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call . This information can also be found on the Investors section of the Innate Pharma website , www.innate-pharma.com . A replay of the webcast will be available on the Company website for 90 days following the event . Pipeline highlights : Lacutamab ( IPH4102 , anti - KIR3DL2 antibody ) : • In February 2021 , the Company announced lacutamab showed a positive early signal in the KIR3DL2 - expressing mycosis fungoides cohort ( cohort 2 ) of the TELLOMAK clinical trial . This cohort reached the pre - determined number of responses needed to advance to stage 2 earlier than anticipated . The Company plans to present this preliminary data as an oral presentation at the 16th International Conference on Malignant Lymphoma , Lugano ( 16 - ICML ) being held virtually between June 18-22 , 2021 . • The Company expects to initiate its Phase 1b trial evaluating lacutamab as a monotherapy in KIR3DL2 - expressing patients with relapsed / refractory peripheral t - cell lymphoma ( PTCL ) by mid - 2021 . In addition , the Lymphoma Study Association ( LYSA ) will initiate an investigator - sponsored , randomized trial to evaluate lacutamab in combination with chemotherapy GEMOX ( gemcitabine in combination with oxaliplatin ) versus GEMOX alone in KIR3DL2 - expressing relapsed / refractory PTCL patients in the second half of 2021 . IPH6101 ( NKp46 - based NK cell engager ) , partnered with Sanofi :